natgillin/translations-raw huggingface dataset:
132 задържане на течности в дробовете; повишена чувствителност на кожата към слънцето; възпаление на кръвоносните съдове; заболяване на кожата, което се характеризира с обелване на кожата по цялото тяло; кожен лупус еритематодес, който се определя като обрив, който може да се появи по лицето, шията и скалпа; алергични реакции; слабост и мускулни спазми; променен сърдечен ритъм; понижено кръвно налягане след промяна в пложението на тялото; подуване на слюнчените жлези; висока кръвна захар; захар в урината; повишение на някои кръвни масти; високи нива на пикочната киселина в кръвта, което може да предизвика подагра.
Additional side effects associated with the other component of Karvezide (hydrochlorothiazide) alone are: loss of appetite; stomach irritation; stomach cramps; constipation; jaundice seen as yellowing of the skin and/ or whites of the eyes; inflammation of the pancreas characterised by severe upper stomach pain, often with nausea and vomiting; sleep disorders; depression; blurred vision; lack of white blood cells, which can result in frequent infections, fever; decrease in the number of platelets (a blood cell essential for the clotting of the blood), decreased number of red blood cells (anaemia) characterised by tiredness, headaches, being short of breath when exercising, dizziness and looking pale; kidney disease; lung problems including pneumonia or build-up of fluid in the lungs; increased sensitivity of the skin to the sun; inflammation of blood vessels; a skin disease characterized by the peeling of the skin all over the body; cutaneous lupus erythematosus, which is identified by a rash that may appear on the face, neck, and scalp; allergic reactions; weakness and muscle spasm; altered heart rate; reduced blood pressure after a change in body position; swelling of the salivary glands; high sugar levels in the blood; sugar in the urine; increases in some kinds of blood fat; high uric acid levels in the blood, which may cause gout.
Всяка филмирана таблетка Karvezide 300 mg/ 25 mg съдържа 300 mg ирбесартан и 25 mg хидрохлоротиазид.
Each film-coated tablet of Karvezide 300 mg/ 25 mg contains 300 mg irbesartan and 25 mg hydrochlorothiazide.
Как изглежда Karvezide и съдържание на опаковката Karvezide 300 mg/ 25 mg филмирани таблетки са розов, двойно изпъкнали, с овална форма, с гравирано сърце от едната страна и числото 2788 гравирано от другата страна.
What Karvezide looks like and contents of the pack Karvezide 300 mg/ 25 mg film-coated tablets are pink, biconvex, oval-shaped, with a heart debossed on one side and the number 2788 engraved on the other side.
Karvezide 300 mg/ 25 mg филмирани таблетки се предлагат в блистерни опаковки от 14, 28, 30, 56, 84, 90 или 98 филмирани таблетки.
Karvezide 300 mg/ 25 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets.
135 Κύπρος ΑΚΗΣ ΠΑΝΑΓΙΩΤΟΥ & ΥΙΟΣ Ε. Π. Ε.
120 Κύπρος ΑΚΗΣ ΠΑΝΑΓΙΩΤΟΥ & ΥΙΟΣ Ε .Π .Ε.
Kentera 3, 9 mg/ 24
Kentera 3.9 mg / 24 hours, transdermal patch
36 mg
Each transdermal patch contains 36 mg of oxybutynin.
24
The area of the patch is 39 cm2, releasing a nominal 3.9 mg of oxybutynin per 24 hours.
.
For excipients, see section 6.1.
,
3.
6. 1.
Transdermal patch.
"
Symptomatic treatment of urge incontinence and/ or increased urinary frequency and urgency as may occur in patients with unstable bladder
.
4.2 Posology and method of administration
,
The patch should be applied to dry, intact skin on the abdomen, hip, or buttock immediately after removal from the protective sachet.
7.
A new application site should be selected with each new patch to avoid reapplication to the same site within 7 days.
Kentera
The recommended dose is one 3.9 mg transdermal patch applied twice weekly (every 3 to 4 days).
. #
No studies have been performed in children or adolescents, therefore Kentera is not recommended for use in children or adolescents.
Kentera
4.3 Contraindications
. $
Hypersensitivity to the active substance or to any other excipients of the transdermal patch.
(
Kentera is contraindicated in patients with urinary retention, severe gastro-intestinal condition, myasthenia gravis or narrow-angle glaucoma and in patients who are at risk for these conditions.
)
4.4 Special warnings and special precautions for use
Kentera.
Kentera should be used with caution in patients with hepatic or renal impairment.
2: &
Urinary Retention:
.
Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic agents such as oxybutynin.
,
2 Kentera should be used with caution in elderly patients, who may be more sensitive to the effects of centrally acting anticholinergics and exhibit differences in pharmacokinetics..
,
Oral administration of oxybutynin may warrant the following cautionary statements, but these events were not observed during clinical trials with Kentera:
Kentera:
Gastrointestinal Disorders:
(
Anticholinergic medicinal products should be used with caution in patients who have autonomic neuropathy, cognitive impairment or Parkinson's disease
/
Oxybutynin may exacerbate the symptoms of hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, tachycardia, hypertension and prostatic hypertrophy
%
Oxybutynin may lead to suppressed salivary secretions which could result in dental caries, parodontosis or oral candidiasis.
%%
4.5 Interaction with other medicinal products and other forms of interaction
%),
The concomitant use of oxybutynin with other anticholinergic medicinal products or with other agents that compete for CYP3A4 enzyme metabolism may increase the frequency or severity of dry mouth, constipation, and drowsiness.
/
Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility.
P 450
As oxybutynin is metabolised by cytochrome P 450 isoenzyme CYP 3A4, interactions with drugs that inhibit this isoenzyme cannot be ruled out.
%,
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or drugs with anticholinergic activity, such as amantadine and other anticholinergic antiparkinsonian drugs (e. g. biperiden, levodopa), antihistamines, antipsychotics (e. g. phenothiazines, butyrophenones, clozapine), quinidine, tricyclic antidepressants, atropine and related compounds like atropinc antispasmodics, dipyridamole.
Kentera.
Oxybutynin may antagonize prokinetic therapies.
,
4.6 Pregnancy and lactation
),
Kentera should not to be used during pregnancy unless clearly necessary
.
Breast feeding while using oxybutynin is therefore not recommended.
.
4.7 Effects on ability to drive and use machines
4. 7
Oxybutynin may cause drowsiness, blurred vision, dizziness and fatigue, therefore caution is recommended when driving or operating machines.
1 -)
4.8 Undesirable effects
+ (1
Other adverse drug reactions reported were dry mouth (Kentera 8.6%, placebo 5.2%), constipation (Kentera 3.9%, placebo 2%), diarrhea (Kentera 3.2%, placebo 2%), headache (Kentera 3.0%, placebo 2.4%), dizziness (Kentera 2.3%, placebo 1.2%), and blurred vision (Kentera 2.3%, placebo 0.89%).
'
Undesirable effects known to be associated with anticholinergic therapy, but not observed with Kentera during clinical studies are anorexia, vomiting, reflux oesophagitis, decreased sweating, heat stroke, decreased lacrimation, mydriasis, tachycardia, arrhythmia, disorientation, poor ability to concentrate, fatigue, nightmares, restlessness, convulsion, intraocular hypertension and induction of glaucoma, confusion, anxiety, paranoia, hallucinations, photosensitivity, erectile dysfunction.
,
Reported Adverse Drug Reactions and rate of occurrence:
,%
Application site reactions
.
All application site reactions -Application site pruritis -Application site erythema -Application site reaction -Application site rash
(Kentera 23, 1%,
23.1% 14.3% 5.7% 3.5% 3.0%
7, 6%). $
Very common very common common common common
(Kentera 8, 6%,
Infections and infestations:
5, 2%),
Urinary Tract Upper Respiratory Tract Fungal Eye disorders
(Kentera 3, 9%,
1.2% 0.2% 0.2%
(Kentera 3, 2%, 2, 3%,
common uncommon uncommon
(Kentera 3, 0%, (Kentera 2, 3%,
Vision abnormalities Ear and labyrinth disorders
2, 4%), 0, 89%).
2.3%
(Kentera
common
Kentera
Dizziness Cardiac Disorders
%%,,,,,
2.3%
,,,,
common
,
Palpitations Vascular disorders
%
0.3%
,,,.
uncommon
"
Hot flushes Urticaria Gastrointestinal disorders
23, 1%
0.3% 0.4%
- - - * - '
uncommon uncommon
:
Dry Mouth Constipation Diarrhea Nausea Abdominal Pain Dyspepsia Abdominal Discomfort Musculoskeletal disorders
14, 3% 5, 7% 3, 5% 3, 0% 1, 2%
8.6% 3.9% 3.2% 2.1% 1.2% 0.4% 0.5%
+ +
common common common common common uncommon uncommon
0, 2% 0, 2%
Back Pain
!
0.8%
2, 3%
uncommon
4 2, 3%
4 Renal and urinary disorders
0, 3%
Urinary retention Dysuria General disorders
0, 3% 0, 4% 8, 6% 3, 9%
0.3% 0.9%
3, 2% 2, 1% 1, 2% 0, 4% 0, 5%
uncommon uncommon
,
Headache Somnolence Rhinitis Injury
0, 3%
3.0% 1.2% 0.5%
0, 9%
common common uncommon
3, 0% 1, 2%
Inflicted Injury
0, 5%
0.3%
0, 3%
uncommon
4. 9 &!
4.9 Overdose
1
Plasma concentration of oxybutynin declines within 1 to 2 hours after removal of transdermal system(s).
Kentera.
No cases of overdose have been reported with Kentera.
2
5.1 Pharmacodynamic properties
3
Pharmacotherapeutic group: urinary antispasmodic, ATC code:
"G04B D04.
G04B D04.
:
Mechanism of action: oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle.
(50: 50)
Pharmacodynamic effects:
R -
The free base form of oxybutynin is pharmacologically equivalent to oxybutynin hydrochloride.
vitro,
Clinical efficacy:
957
A total of 957 patients with urge urinary incontinence were evaluated in three controlled studies comparing Kentera to either placebo, oral oxybutynin and/ or tolterodine long acting capsules.
Kentera
Kentera led to consistent improvements in overactive bladder symptoms compared with placebo.
4 - Kentera,
5 5.2 Pharmacokinetic Properties
%
Absorption Kentera has a concentration of oxybutynin sufficient to maintain continuous transport over the 3 to 4 day dosing interval.
stratum corneum
Oxybutynin is transported across intact skin and into the systemic circulation by passive diffusion across the stratum corneum.
24
Following the application of Kentera, oxybutynin plasma concentration increases for approximately 24 to 48 hours, reaching average maximum concentrations of 3 to 4ng/ ml.
96
Thereafter, steady concentrations are maintained for up to 96 hours.
. *
The volume of distribution was estimated to be 193 l after intravenous administration of 5 mg oxybutynin hydrochloride.
AUC
Transdermal administration of oxybutynin bypasses the first-pass gastrointestinal and hepatic metabolism, reducing the formation of the N-desethyl metabolite.
Cmax
Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.
Kentera
5.3 Preclinical Safety Data
,
In the subcutaneous fertility study in rats, while no effects were reported in males, in females, fertility was impaired and a NOAEL (no observed adverse effect level) of 5 mg/ kg was identified.
6 5. 3
6 PHARMACEUTICAL PARTICULARS
, 0, 4 mg/ kg /
6.1 List of Excipients
,
The release liner is two overlapped siliconised polyester strips that are peeled off and discarded by the patient prior to applying the patch.
5 - # (: /
Backing Film:
(PET/ EVA),
Polyethylene/ ethyl vinyl acetate (PET/ EVA), clear
+ # *:
6 Middle layer:
:
Release Liner:
6. 2
6.2 Incompatibilities
2.
2 years.
. $. $
Store in the original package.
. '
Do not refrigerate.
. #
Do not freeze.
.
6.5 Nature and contents of container
,
The transdermal patches are individually contained in LDPE/ paper laminate sachets and supplied in Patient Calendar Boxes of 2, 8 or 24 patches.
$
6.6 Instructions for use and handling
,
Used patches should not be flushed down the toilet nor placed in liquid waste disposal systems.
,
Do not expose the patch to the sun.
.!
7.
Nicobrand Limited 189 Castleroe Road Coleraine / BT51 3RP
Nicobrand Limited 189 Castleroe Road Coleraine Northern Ireland BT51 3RP
EU/ 1/ 03/ 270/ 001 EU/ 1/ 03/ 270/ 002 EU/ 1/ 03/ 270/ 003
EU/ 1/ 03/ 270/ 001 EU/ 1/ 03/ 270/ 002 EU/ 1/ 03/ 270/ 003
7
7 9.
15. 06. 2004.
15/ 06/ 2004
8 II
8 ANNEX II
6
9 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
7 6
Name and address of the manufacturer responsible for batch release
Nicobrand Limited 189 Castleroe Road, Coleraine BT51 3RP /
Nicobrand Limited 189 Castleroe Road, Coleraine BT51 3RP Northern Ireland
B
B CONDITIONS OF THE MARKETING AUTHORISATION
.
• OTHER CONDITIONS
•
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
10 III
10 ANNEX III
12
12 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
(/ & $5 8
CARTON (Containing 8 transdermal patches)
# +
1.
Kentera 3, 9 mg/ 24 Oxybutynin
Kentera 3.9 mg / 24 hours transdermal patch Oxybutynin
36 mg
Each patch contains 36 mg oxybutynin.
24
The area of the patch is 39 cm2 releasing a nominal 3.9 mg of oxybutynin per 24 hours.
).
4.
8
8 transdermal patches
2
Do not use if seal on sachet is broken
(8
Read the package leaflet before use.
..
6.
6.
Keep out of the reach and sight of children.
4.
7.
7.
8.
.
Exp.
: < 0 0 / + + > ++
Date :< MM/YYYY >
. $. $
Store in original package.
10.
Do not refrigerate.
11.
Do not freeze.
EU/ 1/ 03/ 270/ 001
EU/ 1/ 03/ 270/ 001
6
MANUFACTURER’ S BATCH NUMBER
2: < >
Batch No. :< >
1.
Medicinal product subject to medical prescription
! / / /
INSTRUCTIONS ON USE
/ 3
Sun/ Wed Mon/ Thu Tue/ Fri Wed/ Sat Thu/ Sun Fri/ Mon Sat/ Tue
14
14 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
(/ & $5 24
CARTON (Containing 24 transdermal patches)
24
24 transdermal patches
2
For transdermal use only Do not use if seal on sachet is broken.
(8
Read package leaflet before use.
)
6.
..
7.
6.
8.
4.
EXPIRY DATE
15 9.
15 9.
EU/ 1/ 03/ 270/ 002
EU/ 1/ 03/ 270/ 002
16
16 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING
2
CARTON (Containing 2 transdermal patches)
..
1.
(
Kentera 3.9 mg / 24 hours transdermal patch Oxybutynin
()
2.
2
2 transdermal patches
EU/ 1/ 03/ 270/ 003
EU/ 1/ 03/ 270/ 003
18
18 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
1.
SACHET (Contains 1 transdermal patch)
(8
1.
2
For transdermal use only
.
Read the package leaflet before use.
..
3.
3.
Exp.
: < MM / + + ++
Date :< MM/YYYY >
5
5.
1
Contains 1 transdermal patch.
19..
19 B.
20
20 PACKAGE LEAFLET
Kentera
Read all of this leaflet carefully before you start using Kentera
,.!
- Keep this leaflet.
%
- If you have further questions, please ask your doctor or your pharmacist.
.
- This medicine has been prescribed for you personally and you should not pass it on to others.
! # +
It may
:
harm them even if their symptoms are the same as yours.
1.) 2.
In this leaflet:
Kentera Kentera
1. What Kentera is and what it is used for 2. Before you use Kentera 3. How to use Kentera 4. Possible side effects 5. Storing Kentera 6.
5.
Further Information
Kentera 3, 9 mg/ 24
Kentera 3.9 mg / 24 h transdermal patch
oxybutynin (
The active substance is oxybutynin.
.
Marketing Authorisation Holder and Manufacturer:
KENTERA
WHAT KENTERA IS AND WHAT IT IS USED FOR
Kentera &
Kentera is a thin, flexible, translucent transdermal patch that you apply to your skin.
2.
Each pack contains either 2, 8 or 24 patches.
6 6
Kentera controls the symptoms of urge incontinence and/ or increased urinary frequency and urgency.
KENTERA
BEFORE YOU USE KENTERA
* Kentera:
Do not use Kentera:
&
If you have allergies to medical tape or other transdermal patches, consult your doctor before using Kentera.
Kentera.
You should discuss this problem with your doctor before using Kentera.
21 & Kentera.
21 If you have digestion problems caused by reduced emptying of the stomach after a meal you should consult your doctor before using Kentera.
Kentera.
Take special care with Kentera:
&,
If you have any of the following: • Liver disease • Kidney disease • Bladder obstruction • Gastrointestinal obstruction • Ulcerative colitis • Generalized muscle weakness • Inflammation of the oesophagus
,
Since treatment with oxybutynin may cause decreased perspiration, there is an increased risk of fever and heat stroke if you are exposed to high environmental temperatures.
Kentera.
Kentera is not recommended for use in children or adolescents.
+ Kentera:
Kentera with food and drink:
& • • •
Drowsiness may be increased by consumption of alcohol.
• • • •
Pregnancy
'#'
Ask your doctor for advice before taking any medicine.
Kentera
Kentera should not to be used during pregnancy unless clearly necessary
Kentera + 0
Lactation
:
Ask your doctor for advice before taking any medicine
'.).
It is not known whether oxybutynin is excreted in human milk.
Kentera
Caution should be exercised when using Kentera when you are breast feeding.
!.) Kentera.
Driving and using machines:
7 -
Kentera may cause drowsiness or blurred vision, requiring caution when driving or operating machines.
Kentera%
Taking other medicines:
.
Please inform your doctor or pharmacist if you are taking or have recently taken other medicinal products whether prescribed or not.
KENTERA
HOW TO USE KENTERA
Kentera
Always take Kentera exactly as your doctor has instructed you.
%
Make sure to wear only one patch at a time and wear your patch continuously, until it is time to apply a new one.
Kentera
Where to Apply
.
Avoid placing the patch in the waistline area to prevent tight clothing from rubbing against the patch.
Kentera
Do not expose the patch the sun.
1
Do not apply a patch to the same place on your body for at least 1 week.
.!
abdomen
+
hips
#,
buttocks
%
How to Apply
Kentera.
Please read all the information below before you begin to apply Kentera.
Kentera:
To apply Kentera:
1:
Step 1:
!)
• Freshly washed, but dry and cool (wait a few minutes after taking a hot bath or shower). • Free of body powder, lotion, and oil. • Free of cuts, rashes or any other skin irritation.
2:
Step 2:
•,. •
Open the sachet that contains the patch.
!
• Tear open along arrows marked on the right side of the sachet as shown in drawing below. • Do not cut the sachet with scissors, which might damage the patch inside. • Pull the patch out. • Apply immediately to your skin; do not keep or store the patch outside the sealed sachet.
23 •;.
23 Step 3:
/
• Gently bend the patch and remove the first piece of protective liner, which covers the sticky surface of the patch. • Without touching the sticky surface, firmly press the patch, adhesive face down, onto the part of the abdomen, hips or buttocks you have selected for application.
4:
Step 4:
•.! •
• Bend the patch back over itself.
, & 1, #
Bathing, showering, swimming and exercise:
":
If the patch comes off:
,
No matter what day this happens, continue with the same twice-a-week schedule for your next patch, even if it means changing the new patch before 3 to 4 days have elapsed.
24!
24 How to Remove
,
If irritation persists, please contact your doctor.
.
Alcohol or other strong solvents may cause skin irritation and should not be used.
,
Used patches should not be flushed down the toilet nor placed in liquid waste disposal systems
!)
4.
, Kentera
POSSIBLE SIDE EFFECTS
Kentera
Like all medicines Kentera can have side effects.
(1
Patients using Kentera may experience the following very common (1 in ten persons) side effect: itching around the site of patch application.
10
If you notice any side effects not mentioned in this leaflet please inform your doctor or pharmacist.
(1
5.
100;,
STORING KENTERA
%
Keep out of the reach and sight of children.
);
Do not refrigerate.
. /
Do not freeze.
Kentera
Do not use Kentera after the date shown on the sachet and the carton.
(1
6.
1000
FURTHER INFORMATION
)
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
KENTERA
25 België/ Belgique/ Belgien Vigilex B. V.
Nederland/ Pays- Bas/ Neiderlande Tel/ Tél: +31 (0) 10 244 73 99
Nederland/ Pays-Bas/ Neiderlande Tel/ Tél: +31 (0)10 244 73 99
. / #, "Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
(') Te.: +44 (0) 28 7086 8733
() Te. :+44 (0)28 7086 8733
9eská republika Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
eská republika Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Velká Británie Tel: +44 (0) 28 7086 8733
Velká Británie Tel: +44 (0)28 7086 8733
Danmark Orion Pharma A/ S Tlf: + 45 49 12 66 00
Danmark Orion Pharma A/ S Tlf: + 45 49 12 66 00
Deutschland Merckle Recordati GmbH Tel: +49 (0) 731 7047 0
Deutschland Merckle Recordati GmbH Tel: +49 (0) 731 7047 0
Eesti Orion Corporation Soome Puh/ Tel: + 358 10 4261
Eesti Orion Corporation Soome Puh/ Tel: + 358 10 4261
:; < >
España
4 6 +30 210- 6773822
Recordati Hellas Pharmaceuticals A. E..: +30 210-6773822
España RECORDATI ESPAÑA, S. L.
RECORDATI ESPAÑA, S. L.
Tel: + 34 91 6591550
Tel: + 34 91 6591550
France BOUCHARA RECORDATI Laboratories Tél: +33 (0) 1 45 19 10 00
France BOUCHARA RECORDATI Laboratories Tél: +33 (0) 1 45 19 10 00
Ireland RECORDATI IRELAND LTD.
Ireland RECORDATI IRELAND LTD.
Tel: +44 (0) 845 0942936
Tel: +44 (0) 845 0942936
Ísland Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Ísland Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Bretland Tel: +44 (0) 28 7086 8733
Bretland Tel: +44 (0)28 7086 8733
Italia RECORDATI Industria Chimica e Farmaceutica S. p. A.
Italia RECORDATI Industria Chimica e Farmaceutica S. p. A.
Tel: +39 02 48787. 1
Tel: +39 02 48787.1
76 8:
Latvija Recordati Hellas Pharmaceuticals A. E.
A Subsidiary of Watson Pharmaceuticals, Inc.
Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
5.:
.: +30 210-6773822
Lielbrit; nija Tel: +44 (0) 28 7086 8733
Lielbrit nija Tel: +44 (0)28 7086 8733
Lietuva Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Lietuva Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Jungtin < Karalyst < Tel: +44 (0) 28 7086 8733
Jungtin Karalyst Tel: +44 (0)28 7086 8733
Luxembourg/ Luxemburg Vigilex B. V.
Luxembourg/ Luxemburg Vigilex B. V.
Pays- Bas / Neiderlande Tel/ Tél: +31 (0) 10 244 73 99
Pays-Bas/ Neiderlande Tel/ Tél: +31 (0)10 244 73 99
Magyarország Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Magyarország Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Nagy- Britannia Tel: +44 (0) 28 7086 8733
Nagy-Britannia Tel: +44 (0)28 7086 8733
Malta Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Malta Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Ir- Renju Unit Tel: +44 (0) 28 7086 8733
Ir-Renju Unit Tel: +44 (0)28 7086 8733
Nederland Vigilex B. V.
26 Nederland Vigilex B. V.
Tel/ Tél: +31 (0) 10 244 73 99
Tel/ Tél: +31 (0)10 244 73 99
Norge Orion Pharma AS Tel: + 47 40 00 42 10
Norge Orion Pharma AS Tel: + 47 40 00 42 10
Österreich Merckle Recordati GmbH Deutschland Tel: +49 (0) 731 7047 0
Österreich Merckle Recordati GmbH Deutschland Tel: +49 (0) 731 7047 0
Polska Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Polska Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Wielka Brytania Tel: +44 (0) 28 7086 8733
Wielka Brytania Tel: +44 (0)28 7086 8733
Portugal JABA RECORDATI S. A.
Portugal JABA RECORDATI S. A.
Tel: ++351 21 4329 500
Tel: ++351 21 4329 500
România Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
România Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Marea Britanie Tel: +44 (0) 28 7086 8733
Marea Britanie Tel: +44 (0)28 7086 8733
Slovenija Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Slovenija Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Velika Britanija Tel: +44 (0) 28 7086 8733
Velika Britanija Tel: +44 (0)28 7086 8733
Slovenská republika Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.
Slovenská republika Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc.